Appointment dossier — Endometrial Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrial Carcinoma
- Carboplatin — Human evidence · 0 positive / 1 negative-mixed · PMID 30036218
- Durvalumab — Human evidence · 0 positive / 1 negative-mixed · PMID 36512912
- Paclitaxel — Human evidence · 0 positive / 1 negative-mixed · PMID 30036218
- Curcumin / Theracurmin — Review evidence · 1 positive · PMID 31354362
- Pembrolizumab — Review evidence · 1 positive · PMID 35736598
- Sacituzumab Govitecan — Animal evidence · 1 positive · PMID 40344963
- Cisplatin — Lab evidence · 0 positive / 1 negative-mixed · PMID 35106124
- Sulfasalazine †Rx — Lab evidence · 0 positive / 1 negative-mixed · PMID 35106124
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07662824 — Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy (United States)
- NCT05647109 — Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer (China)
- NCT06893861 — Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer (Italy)
- NCT07407959 — Screening and Staging of Benign vs Malignant Pelvic Abnormalities (United States)
- NCT06851663 · Phase 2 / Phase 3 — Trop2-targeted immunoPET Imaging of Solid Tumors (China)
- NCT05867251 · Phase 1 / Phase 2 — Study of AVZO-021 in Patients With Advanced Solid Tumors (United States)
- NCT07593820 · Phase 1 — A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. (Spain)
- NCT05208762 · Phase 1 — A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (United States)
- NCT05349227 — Comprehensive Outcomes for After Cancer Health (United States)
- NCT06584032 · Phase 3 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer (China)
- NCT06712472 · Phase 3 — Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer (France)
- NCT06481592 · Phase 2 — A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. (United States)
- NCT06522828 · Phase 2 — A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (China)
- NCT06023862 · Phase 2 — A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (Australia)
- NCT07643012 — Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer (United States)
- NCT06656949 — Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer (China)
- NCT05635123 — A Cohort Study of Uterine Malignancies (China)
- NCT06935305 — OSNA Versus Ultrastaging to Detect Sentinel Lymph Node Metastasis in Endometrial Cancer (Italy)
Most-relevant first: trials that name Endometrial Carcinoma, then broader trials you may still qualify for. 337 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Curcumin / Theracurmin × CYP3A4/P-gp substrates (e.g., TKIs, chemo) (high-stakes) — Monitor (moderate)
- Curcumin / Theracurmin × Anticoagulants (high-stakes) — Monitor (minor)
- Curcumin / Theracurmin × Platinum chemotherapy (high-stakes) — Consider (beneficial)
- Sulfasalazine †Rx × sulfa_allergy_drugs (high-stakes) — Contraindicate (high)
- Sulfasalazine †Rx × folate_antagonists — Monitor (moderate)
- Sulfasalazine †Rx × Cisplatin — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Endometrial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Durvalumab has been studied in people for Endometrial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Endometrial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07662824), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?